BML Capital Management LLC Acquires 26,000 Shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA)

BML Capital Management LLC raised its holdings in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 10.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 269,839 shares of the company’s stock after buying an additional 26,000 shares during the quarter. Lisata Therapeutics accounts for approximately 0.6% of BML Capital Management LLC’s holdings, making the stock its 24th biggest holding. BML Capital Management LLC owned approximately 3.31% of Lisata Therapeutics worth $737,000 at the end of the most recent quarter.

Lisata Therapeutics Stock Performance

LSTA opened at $2.65 on Wednesday. The firm’s 50-day simple moving average is $3.03 and its 200-day simple moving average is $2.71. Lisata Therapeutics, Inc. has a twelve month low of $1.95 and a twelve month high of $4.53. The firm has a market cap of $22.01 million, a price-to-earnings ratio of -1.03 and a beta of 1.04.

Lisata Therapeutics (NASDAQ:LSTA) last posted its earnings results on Thursday, February 29th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.20. As a group, sell-side analysts anticipate that Lisata Therapeutics, Inc. will post -3.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Lisata Therapeutics in a report on Friday, March 1st.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.